PMC:7195088 / 33979-34267 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T50","span":{"begin":88,"end":92},"obj":"Body_part"},{"id":"T51","span":{"begin":88,"end":90},"obj":"Body_part"}],"attributes":[{"id":"A50","pred":"fma_id","subj":"T50","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A51","pred":"fma_id","subj":"T51","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"int: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Pr"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T175","span":{"begin":226,"end":234},"obj":"Disease"}],"attributes":[{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"int: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Pr"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T190","span":{"begin":241,"end":246},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"int: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Pr"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T462","span":{"begin":50,"end":61},"obj":"Chemical"},{"id":"T463","span":{"begin":88,"end":90},"obj":"Chemical"},{"id":"T465","span":{"begin":102,"end":112},"obj":"Chemical"},{"id":"T466","span":{"begin":176,"end":187},"obj":"Chemical"},{"id":"T467","span":{"begin":241,"end":246},"obj":"Chemical"}],"attributes":[{"id":"A462","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A463","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A464","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A465","pred":"chebi_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A466","pred":"chebi_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A467","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"int: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Pr"}

{"project":"LitCovid-sentences","denotations":[{"id":"T274","span":{"begin":34,"end":235},"obj":"Sentence"},{"id":"T275","span":{"begin":236,"end":285},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"int: treatment success at day 15.\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Pr"}